1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 02 NOVEMBER 2015

Cancer Drug News 02 NOVEMBER 2015

  • November 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - World's First Oncolytic Viral Therapy Adds Contender To Melanoma Market
Industry Brief - Igenica/MedImmune Enter Oncology Research Collaboration
Industry Brief - Celgene's Vidaza Approved In Europe For Elderly Patients With AML
Industry Brief - Stemline's SL-401 Gains EU Orphan Designation For BPDCN
Industry Brief - Keytruda Superior To Chemotherapy In PD-L1-Expressing NSCLC
Industry Brief - Telesta/Ipsen Sign Ex-US Licensing Deal For MCNA In High-Risk NMIBC
Industry Brief - Keytruda Gains FDA Breakthrough Therapy Designation For Advanced CRC
Industry Brief - FDA Approves Yervoy As Adjuvant Treatment For Stage III Melanoma
Industry Brief - Lenvima Launched In Switzerland
Industry Brief - Kite To License AIS' TIP Technology To Advance CAR/TCR Product Candidates
Industry Brief - MacroGenics Regains Global Rights To Enoblituzumab
Industry Brief - ProBioGen and Bio Farma Enter Trastuzumab Agreement
Industry Brief - Orexo Settles Fentanyl Litigation With Actavis
Industry Trend Analysis - Metabolic And Oncology Areas To Support Growth Prospects

Table Of Contents

Cancer Drug News 02 NOVEMBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025 Summary Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.